Pharmafile Logo

Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

Director Marc Yates looks at the problem of patient compliance – can a better understanding of patient attitudes, needs and behaviours help pharma develop strategies to improve adherence?

Consider the scenario – the physician has been detailed, is sold on your brand’s benefits and prescribes it to the patient. Unfortunately the patient, perhaps unconvinced of what the drug will do for them, either doesn’t fill the prescription or fails to adhere properly to the treatment regime – that’s assuming they even present in the first place. It’s a common problem, especially for chronic diseases like diabetes, hypertension and osteoporosis, and one the pharmaceutical industry has invested much time and money trying to solve. Some companies have responded by developing sophisticated technological solutions, such as wireless devices, that remind patients when to take their medication. Unfortunately these solutions have not raised adherence levels because they have failed to get to the heart of the matter. To develop an effective adherence strategy, you first need to develop a more in-depth understanding of the attitudes and behaviours of both the patient and the physician, and the relationship which exists between them.

Download and read the complimentary whitepaper at http://bit.ly/1R0gWjr

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.
 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report

The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here

Event: Blending data science and market research at the Data Analytics & Insight conference

Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be...

Presentation: Optimize your digital assets with UX research

US Director Liza Pliss recently presented the paper 'Optimize your digital assets with UX research' at the PMR Conference in New Jersey, USA. Don't worry if you missed it though,...

Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase

We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight

In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...

Report: Living with RA (EU, Japan and Canada) 2019 reports

Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...

News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)

A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...